Bipolar disorder is a mental disorder. It is also called manic depression. Bipolar disorder happens within two phases of mood periods. One is the period of depression and the other is the period of elevation. The elevation mood is also called hypomania. During the period of hypomania, an individual feels extremely energetic, irritable, and happy. In depression mood, an individual feels loss of energy, loss of memory, and sadness. Both environmental and genetic factors are responsible for bipolar disorder. Many people are addicted to alcohol and drugs when they enter the phase of manic depression. Those afflicted with seasonal depression, and anxiety disorders such as post-traumatic stress disorder (PTSD) are also likely to have bipolar disorder. Chances of suicide and self-harm are maximum in both the phases. Bipolar disorder can affect both male and female and the most common age of affliction is around 25 years.
Obtain Report Details: http://www.transparencymarketresearch.com/bipolar-disorder-therapeutic-market.html
On the basis of treatment, the bipolar disorder therapeutic market is segmented into psychotherapy treatment such as mood stabilizers and medication treatment such as use of antipsychotics drugs. Lithium and anticonvulsants are the two mood stabilizer drugs currently used. Depending upon use, antipsychotics drugs are divided into typical antipsychotics drugs and atypical antipsychotic drugs. Both the classes of drugs are used for the treatment of bipolar disorder. However, atypical antipsychotics drugs are mostly used as they are more effective and have less side effects than the typical antipsychotics drugs because atypical drugs are second generation drugs and act on both dopamine and serotonin receptor of the brain. Lurasidone, olanzapine, and quetiapine are some drugs most widely used in the treatment of bipolar disorder. Proper diagnosis and treatment help people affected by bipolar disorder to lead a healthy and productive life. Electroconvulsive therapy is one of the best therapies that can provide relief to those suffering from severe bipolar disorder, followed by magnetic seizure therapy, vagus nerve stimulation therapy, and repetitive transcranial magnetic stimulation therapy. It is a brain stimulation therapy in which electric current is used to treat the serious mental disorder. This type of therapy is carried out only when other therapy is not helpful. Consumption of alcohol, mental stress, and use of abuse drugs are major factors driving the market of bipolar drugs. However, side effects of anticonvulsants, stringent regulatory frameworks, and limited approval of anticonvulsants are some of the factors that hamper the growth of the market.
Geographically, the global bipolar disorder therapeutic drugs market is dominated by North America due to increased awareness and numerous treatment options. According to statistics from community studies of European Union countries like Iceland and Norway, 27% of adults suffer from one time bipolar disorder. European Health Information Initiative helps to gather information to deepen the understanding of the health with a focus indicator. Launching the evidence informed policy network are expanding the market size and growth. Asia Pacific is expected to be the fastest growing market in the region. In India and China, alcohol consumption and growing stress are increasing day by day with the increasing population. Rising awareness about mental illness and improving economy drives the market in Middle East & Africa.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=25256
Eli Lilly and Company, GlaxoSmithKline plc., Merck & Co., Inc., Johnson & Johnson, Pfizer Inc., Forest Laboratories. Otsuka America Pharmaceutical Inc. and Novartis are some major pharmaceutical companies active in the bipolar disorder therapeutic market.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Obtain Report Details: http://www.transparencymarketresearch.com/bipolar-disorder-therapeutic-market.html
On the basis of treatment, the bipolar disorder therapeutic market is segmented into psychotherapy treatment such as mood stabilizers and medication treatment such as use of antipsychotics drugs. Lithium and anticonvulsants are the two mood stabilizer drugs currently used. Depending upon use, antipsychotics drugs are divided into typical antipsychotics drugs and atypical antipsychotic drugs. Both the classes of drugs are used for the treatment of bipolar disorder. However, atypical antipsychotics drugs are mostly used as they are more effective and have less side effects than the typical antipsychotics drugs because atypical drugs are second generation drugs and act on both dopamine and serotonin receptor of the brain. Lurasidone, olanzapine, and quetiapine are some drugs most widely used in the treatment of bipolar disorder. Proper diagnosis and treatment help people affected by bipolar disorder to lead a healthy and productive life. Electroconvulsive therapy is one of the best therapies that can provide relief to those suffering from severe bipolar disorder, followed by magnetic seizure therapy, vagus nerve stimulation therapy, and repetitive transcranial magnetic stimulation therapy. It is a brain stimulation therapy in which electric current is used to treat the serious mental disorder. This type of therapy is carried out only when other therapy is not helpful. Consumption of alcohol, mental stress, and use of abuse drugs are major factors driving the market of bipolar drugs. However, side effects of anticonvulsants, stringent regulatory frameworks, and limited approval of anticonvulsants are some of the factors that hamper the growth of the market.
Geographically, the global bipolar disorder therapeutic drugs market is dominated by North America due to increased awareness and numerous treatment options. According to statistics from community studies of European Union countries like Iceland and Norway, 27% of adults suffer from one time bipolar disorder. European Health Information Initiative helps to gather information to deepen the understanding of the health with a focus indicator. Launching the evidence informed policy network are expanding the market size and growth. Asia Pacific is expected to be the fastest growing market in the region. In India and China, alcohol consumption and growing stress are increasing day by day with the increasing population. Rising awareness about mental illness and improving economy drives the market in Middle East & Africa.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=25256
Eli Lilly and Company, GlaxoSmithKline plc., Merck & Co., Inc., Johnson & Johnson, Pfizer Inc., Forest Laboratories. Otsuka America Pharmaceutical Inc. and Novartis are some major pharmaceutical companies active in the bipolar disorder therapeutic market.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
No comments:
Post a Comment